Molecular regulatory mechanism of LILRB4 in the immune response

被引:2
|
作者
Liu, Haiyin [1 ,2 ,3 ]
Yang, Jun [1 ,2 ,4 ]
Zhang, Jing [2 ,3 ]
Zhang, Peiyue [1 ,2 ,3 ]
Zhang, Mengting [1 ,2 ,3 ]
Yang, Chaojun [2 ,3 ]
Liu, Li [2 ,3 ]
Huang, Cuiyuan [3 ]
Wang, Wei [2 ,3 ]
Zhai, Yuhong [1 ,2 ,3 ]
Yang, Jian [1 ,2 ]
机构
[1] China Three Gorges Univ, Coll Clin Med Sci 1, Dept Cardiol, Yichang, Peoples R China
[2] China Three Gorges Univ, Inst Cardiovasc Dis, Yichang, Peoples R China
[3] HuBei Clin Res Ctr Ischem Cardiovasc Dis, Yichang, Peoples R China
[4] China Three Gorges Univ, Coll Clin Med Sci 1, Dept Cardiol, Yichang 443000, Peoples R China
基金
中国国家自然科学基金;
关键词
LILRB4; SHP-1; immune disease; molecular mechanism; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; NEGATIVE REGULATION; UP-REGULATION; TRANSCRIPT; RECEPTOR B4; EXPRESSION; ILT3; INDUCTION; DIFFERENTIATION;
D O I
10.5114/ceji.2023.125238
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immune diseases are caused by the imbalance of immune regulation. This imbalance is regulated by many factors, both negative and positive. Leukocyte immunoglobulin-like receptor B4 (LILRB4) is a member of leukocyte immunoglobulin-like receptors (LILRs). LILRs are expressed constitutively on the surface of multiple immune cells which associate with membrane adaptors to signal through multi-ple cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or immunoreceptor tyro-sine-based activation motifs (ITAMs). Through ITIM, LILRB4 could recruit the src homology domain type-2-containing tyrosine phosphatase 1 or 2 (SHP-1 or SHP-2) into the cell membrane. In addition, many factors can induce the expression of LILRB4, such as vitamin D, interferon and so on. Studies have demonstrated that LILRB4 had a negative regulatory role in various of immune diseases. The present review intends to expound the structure and function of LILRB4, as well as its regulators and receptors in the immune cells, so as to provide a theoretical basis for immune disease therapy.
引用
收藏
页码:43 / 47
页数:5
相关论文
共 50 条
  • [1] LILRB4, an immune checkpoint on myeloid cells
    Yang, Ting
    Qian, Yixin
    Liang, Xiaoting
    Wu, Jianbo
    Zou, Ming
    Deng, Mi
    BLOOD SCIENCE, 2022, 4 (02): : 49 - 56
  • [2] Biomimetic design of inhibitors of immune checkpoint LILRB4
    Chao, Yuanyuan
    Zhang, Lin
    BIOPHYSICAL CHEMISTRY, 2022, 282
  • [3] LILRB4, from the immune system to the disease target
    Liu, Jiachen
    Wu, Qiwen
    Shi, Jing
    Guo, Weihua
    Jiang, Xingjun
    Zhou, Bolun
    Ren, Caiping
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (07): : 3149 - 3166
  • [4] LILRB4 Checkpoint for Immunotherapy: Structure, Mechanism and Disease Targets
    Xiang, Zhiqing
    Yin, Xiangli
    Wei, Leiyan
    Peng, Manqing
    Zhu, Quan
    Lu, Xiaofang
    Guo, Junshuang
    Zhang, Jing
    Li, Xin
    Zou, Yizhou
    BIOMOLECULES, 2024, 14 (02)
  • [5] LILRB4 Expression in CMML and MDS Based on Response to Hypomethylating Agents
    Chien, Kelly
    Class, Caleb
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Naqvi, Kiran
    Gomez, Irene Ganan
    Wei, Yue
    Yang, Hui
    Kanagal-Shamanna, Rashmi
    Soltysiak, Kelly
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S341 - S341
  • [6] LILRB4 expression in CMML and MDS based on response to hypomethylating agents.
    Chien, Kelly Sharon
    Class, Caleb A.
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Naqvi, Kiran
    Gomez, Irene Ganan
    Wei, Yue
    Yang, Hui
    Kanagal-Shamanna, Rashmi
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] LILRB4 as a novel immunotherapeutic target for multiple diseases
    Wang, Xu
    Li, Lanying
    Liu, Dan
    Jin, Yuhang
    Zhao, Xuan
    Li, Sijin
    Hou, Rui
    Guan, Zhangchun
    Ma, Wen
    Zheng, Junnian
    Lv, Ming
    Shi, Ming
    BIOCHEMICAL PHARMACOLOGY, 2025, 233
  • [8] LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents
    Chien, Kelly S.
    Class, Caleb A.
    Montalban-Bravo, Guillermo
    Wei, Yue
    Sasaki, Koji
    Naqvi, Kiran
    Ganan-Gomez, Irene
    Yang, Hui
    Soltysiak, Kelly A.
    Kanagal-Shamanna, Rashmi
    Do, Kim-Anh
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1493 - 1499
  • [9] In vitro characterization of a dual antagonistic anti-LILRB2/LILRB4 monoclonal antibody
    Daugherty, Bruce L.
    Ge, Xiaomei
    Hsieh, Christine L.
    Zabel, Brian A.
    Lederman, Seth
    CANCER RESEARCH, 2024, 84 (06)
  • [10] Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML
    Morse, Joshua W.
    Gui, Xun
    Deng, Mi
    Huang, Ryan
    Ye, Xiaohua
    Zhao, Peng
    Fan, Xuejun
    Xiong, Wei
    Zhang, Chengcheng
    Zhang, Ningyan
    An, Zhiqiang
    ANTIBODY THERAPEUTICS, 2023, 7 (01) : 13 - 27